A Study on the Efficacy and Gut Microbiota of Berberine and Probiotics in Patients With Newly Diagnosed Type 2 Diabetes

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 400 participants.

Also called NCT02861261

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 400 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT02861261
Other papers using this trial's data
  • Gut microbiome-related effects of berberine and probiotics on type 2 diabetes (the PREMOTE study) Nature communications, 2020-10-06 DOI, PubMed 33024120, PMC7538905 In the PMC Open Access subset under CC BY.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT02861261. Randomized; double masking; primary purpose treatment. Start 2016-08-18 (actual); primary completion 2017-12 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study on the Efficacy and Gut Microbiota of Berberine and Probiotics in Patients With Newly Diagnosed Type 2 Diabetes
Intervention (Drug)
1. Berberine hydrochloride tablets ; 2. ProMetS probiotics powder
Intervention (Drug)
1. Berberine placebo tablets ; 2. ProMetS probiotics powder
Intervention (Drug)
1. Berberine hydrochloride tablets; 2. Probiotics placebo powder
Intervention (Drug)
1. Berberine placebo tablets; 2. Probiotics placebo powder
Lead sponsor
Shanghai Jiao Tong University School of Medicine (class: other)

Record details

Record id
cardio:ct-nct02861261
Content hash
96c7c3cef309b7248f625d5d876147868a664bfc1ee5847bb83e48c8ad1ab8c0